ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1854

The Involvement Of Mast Cells In The Development Of Lung Fibrosis Via Modulating Pulmonary Fibroblast Immune Function

Shinjiro Kaieda1, Morihisa Tajiri2, Masaki Okamoto3, Naomi Yoshida4, Hiroaki Ida5, Tomoaki Hoshino4 and Takaaki Fukuda6, 1Department of Medicine, *Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, kurume, Japan, 2Department of Internal Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 3Department of Internal medicine, Division of respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 4Department of Medicine, Division of Respirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 5Department of Internal Medicine, Division of REspirology, Neurology and Rheumatology, Kurume University School of Medicine, Kurume, Japan, 6Center for Rheumatic Diseases, Kurume University Medical Center, Kurume, Japan

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Fibroblasts and mast cells

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis II

Session Type: Abstract Submissions (ACR)

Background/Purpose: Idiopathic pulmonary fibrosis (IPF) is an interstitial lung disease of unknown etiology; the most critical event in the evolution of fibrosis is the appearance of activated myofibroblasts. Mast cells (MC) mediate a variety of inflammatory and fibrotic conditions, but their role in IPF is unclear. We examined whether MCs play a critical role in the development of pulmonary fibrosis.

Methods: Lung tissue was examined using histology and immunohistochemistry. Bioptic material was obtained from the involved lung tissue of 18 IPF patients. As control samples, we used 8 noncancerous lung sections from patients who had undergone surgery for lung cancer. We used immunohistochemistry to identify and quantify tryptase-positive MCs, prolyl-4-hydroxylase β-positive fibroblasts, and alpha-smooth muscle actin (α-SMA)-positive myofibroblasts. Co-culture of human mast cell line 1 (HMC-1) with pulmonary fibroblasts was performed in a transwell system. Fibroblasts cultured with HMC-1 cells for 7 days were cytospun and expression of α-SMA, a marker of myofibroblast differentiation, was examined by immunohistochemistry. α-SMA gene (Acta2) expression in fibroblasts, and IL-6, TGF-β, and bFGF in HMC-1 cells and fibroblasts were evaluated by RT-qPCR.

Results:

MCs were significantly more numerous in IPF than control lung tissue. MCs were usually in close proximity to pulmonary fibroblasts and myofibroblasts. Up-regulation of α-SMA in fibroblasts during co-culture with MCs was confirmed by immunohistochemistry; Acta2 mRNA was also significantly elevated. In co-cultures of fibroblasts and HMC-1 cells, IL-6, TGF-b, and bFGF expression increased in the HMC-1 cells and IL-6 and TGF-b expression increased in the fibroblasts. These observations suggest an amplification loop is generated between MCs and fibroblasts, enhancing production of pro-fibrotic factors.


Conclusion:

These findings suggest a novel role for MCs in the development of lung fibroblasts via induction of myofibroblast differentiation. An amplification loop between MCs and fibroblasts enhances production of pro-fibrotic factors including TGF-b and bFGF, which may contribute to myofibroblast differentiation and activation.


Disclosure:

S. Kaieda,
None;

M. Tajiri,
None;

M. Okamoto,
None;

N. Yoshida,
None;

H. Ida,
None;

T. Hoshino,
None;

T. Fukuda,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/the-involvement-of-mast-cells-in-the-development-of-lung-fibrosis-via-modulating-pulmonary-fibroblast-immune-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology